Biogen

Biogen logo
🇺🇸United States
Ownership
Private
Established
1978-01-01
Employees
7.5K
Market Cap
$29.6B
Website
https://www.biogen.com
Introduction

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Peginterferon Beta-1a (BIIB017) Autoinjector Pharmacokinetic Study in Healthy Volunteers

First Posted Date
2012-06-04
Last Posted Date
2014-06-13
Lead Sponsor
Biogen
Target Recruit Count
55
Registration Number
NCT01610310
Locations
🇺🇸

Research Site, St. Paul, Minnesota, United States

Exploratory Study to Assess the Effect of Fampridine (BIIB041) on Walking Ability and Balance in Participants With Multiple Sclerosis.

First Posted Date
2012-05-14
Last Posted Date
2017-01-09
Lead Sponsor
Biogen
Target Recruit Count
132
Registration Number
NCT01597297
Locations
🇬🇧

Research Site, London, United Kingdom

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

First Posted Date
2012-04-02
Last Posted Date
2016-06-13
Lead Sponsor
Biogen
Target Recruit Count
173
Registration Number
NCT01568112
Locations
🇺🇸

Research Site, St Paul, Minnesota, United States

Crossover Study of CNV1014802 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-03-22
Last Posted Date
2017-10-13
Lead Sponsor
Biogen
Target Recruit Count
82
Registration Number
NCT01561027
Locations
🇸🇪

Research Site, Stockholm, Sweden

MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia

First Posted Date
2012-03-16
Last Posted Date
2013-09-16
Lead Sponsor
Biogen
Target Recruit Count
180
Registration Number
NCT01556685
Locations
🇲🇽

Research Site, Leon, Guanajuato, Mexico

A Phase IIa Withdrawal Study of CNV1014802 in Patients With Trigeminal Neuralgia

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-02-29
Last Posted Date
2019-01-10
Lead Sponsor
Biogen
Target Recruit Count
67
Registration Number
NCT01540630
Locations
🇬🇧

Professor Joanna Zakrzewska, London, United Kingdom

Fampridine Pregnancy Exposure Registry

Terminated
Conditions
First Posted Date
2012-02-14
Last Posted Date
2016-10-18
Lead Sponsor
Biogen
Target Recruit Count
1
Registration Number
NCT01532154
Locations
🇫🇷

Hopital Pitie Salpetriere, Paris, France

A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-04958242 In Psychiatrically Stable Subjects With Schizophrenia

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-01-26
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
30
Registration Number
NCT01518894
Locations
🇺🇸

Pfizer Investigational Site, Long Beach, California, United States

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-01-26
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
44
Registration Number
NCT01518920
Locations
🇺🇸

Pfizer Investigational Site, Dallas, Texas, United States

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Repeated Doses of PF-04958242 in Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-01-18
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
39
Registration Number
NCT01511510
Locations
🇺🇸

Pfizer Investigational Site, New Haven, Connecticut, United States

© Copyright 2024. All Rights Reserved by MedPath